Categories: AutoimmuneBiotechBiotechnologyDrugDiscoveryImmunologyNeuroscienceTherapeutics
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.10.2025 | Series A | $101M | DCVC |
Mentions in press and media 5
| Date | Title | Description |
| 15.10.2025 | Nilo Therapeutics Secures $101M for Neuro-Immunology Revolution | Nilo Therapeutics launched with $101 million Series A funding. The neuro-immunology biotech seeks to restore immune balance. It modulates neural circuits, targeting autoimmune and inflammatory diseases. Key investors include The Column Grou... |
| 13.10.2025 | Nilo Therapeutics: $101 Million Series A Raised For Advancing Neuro-Immunology Drug Platform | Nilo Therapeutics, a biotechnology company focused on restoring immune balance through neural circuit modulation, has launched with $101 million in Series A funding. The round was led by The Column Group (TCG), DCVC Bio, and Lux Capital, wi... |
| 09.10.2025 | Nilo Therapeutics Raises $101M in Series A Financing | Nilo Therapeutics, a NYC-based biotechnology company harnessing neural circuits to restore immune homeostasis in disease, launched with a $101m Series A financing.
The round was led by The Column Group (TCG), DCVC Bio, and Lux Capital, with... |
| 08.10.2025 | Immunology biotech Nilo launches with $101M and mission to harness neural circuits | Nilo Therapeutics has launched with $101 million in series A funds to drive its ambition to harness neural circuits to restore immune homeostasis.
The New York-headquartered company was founded by a trio of respected academics in Columbia U... |
| - | NILO Therapeutics | “A neuronal circuit regulates the immune system. We're targeting it to treat autoimmune and inflammatory diseases.” |
Reviews 0
